Compare PRSO & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRSO | SILO |
|---|---|---|
| Founded | 2008 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Apparel |
| Sector | Technology | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8M | 7.2M |
| IPO Year | 2000 | 2011 |
| Metric | PRSO | SILO |
|---|---|---|
| Price | $1.05 | $0.59 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | 549.9K | ★ 4.1M |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.23 | 57.98 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $14,573,000.00 | $72,102.00 |
| Revenue This Year | $18.48 | $1.86 |
| Revenue Next Year | $53.57 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.99 | N/A |
| 52 Week Low | $0.75 | $0.22 |
| 52 Week High | $2.37 | $1.18 |
| Indicator | PRSO | SILO |
|---|---|---|
| Relative Strength Index (RSI) | 49.91 | 65.28 |
| Support Level | $0.81 | $0.29 |
| Resistance Level | $1.05 | $0.62 |
| Average True Range (ATR) | 0.06 | 0.07 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 68.33 | 71.03 |
Peraso Inc is a fabless semiconductor company focused on the development and sale of: i) millimeter wavelength wireless technology, or mmWave, semiconductor devices and antenna modules based on its proprietary semiconductor devices and ii) performance of non-recurring engineering, or NRE, services and licensing of intellectual property, or IP. The company's primary focus is the development of mmWave, which is generally described as the frequency band from 24 Gigahertz, or GHz, to 300 GHz. Geographically the company generates revenue from the United States, Hong Kong, Taiwan, and the Rest of the World.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's product pipelines include: SPC-14, SPC-15, SP-26, and SPU-16. The company operates as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical need.